- A-Z Publications
- Southern African Journal of HIV Medicine
- Previous Issues
- Volume 2005, Issue 18, 2005
Southern African Journal of HIV Medicine - Volume 2005, Issue 18, 2005
Volumes & issues
Volume 2005, Issue 18, 2005
Author Des MartinSource: Southern African Journal of HIV Medicine 2005 (2005)More Less
Extracted from text ... THE SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE MARCH 2005 55 Even after five years of intensive activity by the Society, and an increase of membership from 300 to 8 600 health care professionals, I am still frequently asked what it means to be a member of the Southern African HIV Clinicians Society. Well, apart from the camaraderie of the executive committee and members, engendered by a collective effort to provide appropriate diagnosis and treatment to southern Africa's HIVinfected and affected, the obvious advantages are: Quarterly publications: ? The Southern African Journal of HIV Medicine ? Transcript (newsletter containing regional ..
Source: Southern African Journal of HIV Medicine 2005, pp 7 –8 (2005)More Less
Extracted from text ... THE SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE MARCH 2005 LOOKING BACK, LOOKING FORWARD More than any other field of medicine, HIV medicine is evol-ving rapidly. Not only are new drugs, new drug targets and new strategies being discovered, but also guidelines must be reviewed continually as new information about how to use them comes to light. The recent flood of controversy in the world media surrounding nevirapine highlights this, and also illustrates the benefit of this sort of information being digested by experts and repackaged for local consumption. There is a need for health care workers to have regular and ..
Source: Southern African Journal of HIV Medicine 2005 (2005)More Less
Extracted from text ... THE SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE MARCH 2005 9 All individuals contemplating HIV testing themselves or faced with it in a loved one, or having recently received a test result - or indeed undergoing any type of HIV treatment - benefit greatly from empathic, expert counselling. There is no doubt that counselling is a significant skill required in HIV care and management. Yet so often the medical profession is far from proficient and often 'too busy' to really do any counselling well. Hence, more than any other field, HIV medicine has embraced professional counsellors as members of the ..
Source: Southern African Journal of HIV Medicine 2005, pp 10 –11 (2005)More Less
Extracted from text ... MARCH 2005 THE SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE 10 FDA Public advisory for Nevirapine (Viramune) PUBLIC HEALTH Recently the US Federal Drug Administration has issued a Public Advisory for Nevirapine (NVP) (Vira-mune) informing health care providers of a safety-related change to the nevirapine package insert. This advisory, issued on 19 January 2005, notified a change in nevirapine prescribing information with a warning against starting nevirapine in women with CD4 counts > 250 cells/?l and in men with counts > 400/?l. The risk of developing a hepatic hypersensitivity reaction in the first 6 weeks of nevirapine therapy had been shown ..
Source: Southern African Journal of HIV Medicine 2005, pp 12 –16 (2005)More Less
Extracted from text ... MARCH 2005 THE SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE 12 CUTANEOUS MANIFESTATIONS OF HIV / AIDS : PART 2 DERMATOLOGY The insidious damage to the immune system by the human immunodeficiency virus results in increasing susceptibility to opportunistic viral infections. These can be localised, widespread, confined to the skin, or systemic. They can cause mild though disfiguring lesions such as molluscum contagiosum (MCV), or lead to life-threatening infections such as human papillomavirus (HPV-induced squamous cell carcinoma. Viral opportunistic infections represent activation of subclinical infection (e.g. HPV, MCV) or reactivation of latent infection, e.g. herpes simplex virus (HSV 1 and ..
Cutaneous manifestations of HIV / AIDS : part 1, Southern African Journal of HIV Medicine, 17, 2004, pp.12-17 : erratumSource: Southern African Journal of HIV Medicine 2005 (2005)More Less
Extracted from text ... Part 1 of the article 'Cutaneous manifestations of HIV/AIDS', which appeared on pp. 12 - 17 of the November 2004 issue of the Southern African Journal of HIV Medicine, contained a sentence that could be misleading. On p. 15 (left-hand column) the dosage of amphotericin B for treating the acute stage of histoplasmosis is given as 15 mg/kg. The dosage is in fact 0.7 mg/kg/d. In response to a reader query, the authors have also clarified the dosage of fluconazole. On p. 13 (right-hand column) it was stated that when oesophageal candidiasis is suspected, fluconazole 100 mg/d should be given for 5 days. The treatment for oral candidiasis that is not responsive to ..
Source: Southern African Journal of HIV Medicine 2005, pp 18 –31 (2005)More Less
Sub-Saharan Africa has just over 10% of the world's population but is home to more than 60% of all people living with HIV (approximately 25.4 million people). Prevalence rates in southern Africa's antenatal clinics surpass 25%, the highest in the world. <br>South Africa is host to the highest number of HIV-infected people in the world (5.3 million, UNAIDS/WHO AIDS epidemic update, December 2004) with considerable regional variation and an annual increase in all but two provinces (Free State and Gauteng). The Free State, Mpumalanga and KwaZulu-Natal have prevalence rates among pregnant women attending public sector antenatal clinics of > 30% while the remaining provinces have a range of between 15% and 17.5%. <br>Four other countries in the region have very high antenatal prevalence rates, often exceeding 40%: Botswana, Lesotho, Namibia and Swaziland (39%). Elsewhere in the sub-region HIV infections in pregnant women appear to be stabilising at lower levels, e.g. Malawi (18%), Zambia (16%) and Zimbabwe (25%). Uganda's prevalence, though still high, has dropped in the last decade to 5 - 6%. Angola is the exception in the region, having had very low prevalence levels for some years, possibly owing to the war which restricted civilian movement. Prevalence remains at about 3% at Luanda's antenatal clinics; however, sex workers have an incidence of 33%, fuelling fears of a widespread and rapid spread in this country. <br>Most sub-Saharan countries have antiretroviral roll-outs, albeit at different stages and levels of delivery. <br>In July 2004, the Health Systems Trust, reported in the first <I>South African Health Review (SAHR)</I> that AIDS was responsible for 39% of deaths in South Africa in 2000. Gearing up for the national antiretroviral (ARV) roll-out in early 2003, the South African government estimated that about half a million South Africans with AIDS were in urgent need of ARV treatment (ART). In March 2003 the Department of Health commenced the national roll-out at a handful of pre-selected, designated pilot sites, aiming to treat 53 000 HIV-infected South Africans (CD4+ counts of < 200/µl) with ARVs by March 2004, and expanding the number of sites over time. To date progress has been slower than planned. National ART guideline regimens are advised in these guidelines.
Author Robin WoodSource: Southern African Journal of HIV Medicine 2005, pp 32 –36 (2005)More Less
Despite the present number of available antiretrovirals (ARVs), there continues to be a need for new medications with improved tolerability, and activity against resistant virus. This article will review three groups of ARVs: those available in North America and Europe but not yet registered in South Africa; new formulations of drugs for which the parent formulations are already available in South Africa; and promising new compounds in early clinical stages of development. Table I shows the year of approval of ARVs available for treatment of HIV-infected individuals, in both the USA and South Africa and Table II summarises the characteristics and rationale for new ARVs.
Extranodal presentation in patients with acquired immunodeficiency syndrome non-Hodgkin's lymphoma (AIDS-NHL) : clinicalAuthor P. BarnardtSource: Southern African Journal of HIV Medicine 2005, pp 37 –40 (2005)More Less
Kaposi's sarcoma, non-Hodgkin's lymphoma (NHL), including primary central nervous system lymphoma (PCNSL), and cervical cancer define the acquired immune deficiency syndrome (AIDS). NHL is the second most common malignancy associated with HIV infection. The clinical presentation varies, and while patients may present with asymptomatic lymphadenopathy, many have extranodal disease. Extranodal lymphomas arise from tissue other than lymph nodes and even sites that normally contain no lymphoid tissue. These lymphomas are referred to as extranodal lymphomas and can arise in almost any organ. AIDS-NHL may present at any point in the course of immunosuppression. This report deals with three case studies that illustrate the spectrum and variety of extranodal presentations in patients with AIDS-NHL.
Source: Southern African Journal of HIV Medicine 2005 (2005)More Less
Extracted from text ... THE SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE MARCH 2005 41 NEWS The low registration of patients on HIV management programmes has received a fair amount of negative publicity recently. However, research suggests that enrolment of those who stand to gain the most benefit from accessing treatment is relatively high. In addition, the inclusion of antiretroviral therapy into the HIV prescribed minimum benefits (PMBs) will have a limited effect on medical schemes. This is according to Rodney Cowlin, managing director for Aid for AIDS, a Medscheme initiative that has been in operation for almost seven years. 'Aid for AIDS has ..
Building bridges of understanding and empowerment between society and researchers : vaccine researchAuthor Michelle Rotchford GallowaySource: Southern African Journal of HIV Medicine 2005, pp 44 –45 (2005)More Less
Extracted from text ... MARCH 2005 THE SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE 44 Michelle Rotchford Galloway, MPhil (Journ) Media and Communications Manager, South African AIDS Vaccine Initiative (SAAVI) VACCINE RESEARCH Building bridges of understanding and empowerment between society and researchers Masikhulisane, meaning 'Let us grow together', is the new name of the revamped and refocused community involvement programme of the South African AIDS Vaccine Initiative (SAAVI). The programme aims to create an equal, meaningful partnership between community and scientists to facilitate AIDS vaccine research and promote overall understanding of medical research. As the programme manager Elise Levendal says: 'It's for us to bring ..